Double-Blind Randomized Controlled Trial of Glutamine-Enriched Polymeric Diet in the Treatment of Active Crohn's Disease

Akobeng, Anthony K; Miller, Vivien; Stanton, J. B.; Elbadri, A.; Thomas, Adrian G

doi:10.1097/00005176-200001000-00022

Cited by 157 publications

(107 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two published human studies on enteral glutamine supplementation in patients with Crohn's disease included a total number of 32 patients (14 adults, 18 children) (Den Hond et al, 1999;Akobeng et al, 2000). Neither study observed an effect of enteral glutamine supplementation (over a 4-week period) on intestinal permeability or inflammatory activity.…”

Section: Discussionmentioning

confidence: 99%

“…However, clinical data supporting this assumption are rare. Only two studies have been published in which gln was administered by an enteral route in 18 and 14 IBD patients (Den Hond et al, 1999;Akobeng et al, 2000). This means that data are only available for 16 IBD patients treated with gln.…”

Section: Introductionmentioning

confidence: 99%

“…This means that data are only available for 16 IBD patients treated with gln. Akobeng et al (2000) investigated a glutamine-enriched enteral diet in children, and Den Hond et al (1999) tested a gln supplement vs placebo in adults with Crohn's disease. A significant beneficial effect of gln supplementation, compared to placebo or a standard enteral formula, was not demonstrated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease

et al. 2005

View full text Add to dashboard Cite

Background: Studies in animal models of inflammatory bowel disease (IBD) suggest that supplementation of total parenteral nutrition with glutamine (gln), a conditionally essential amino acid in catabolic conditions, increases gln plasma concentrations, reduces intestinal damage, improves nitrogen balance and may improve the course of the disease. However, human data supporting this assumption are missing. Methods: A total of 24 consecutive patients with an acute exacerbation of IBD (19 Crohn's disease; five ulcerative colitis) and scheduled for total parenteral nutrition (TPN) (47 days) were randomised. Parallel to a standardised anti-inflammatory therapy, the patients received either a TPN with 1.5 g/kg body weight of a standard amino acid or an isonitrogenic, isocaloric TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine. Primary end points were gln plasma concentrations and intestinal permeability assessed by urinary lactulose and D-xylose ratio. Results: Gln plasma levels did not differ significantly in either group throughout the study. Intestinal permeability did not change within 7 days either with or without gln supplementation (D-lactulose/xylose ratio: 0.0170.05 (gln þ ) vs 0.0270.1 (glnÀ)). The observed changes in inflammatory and nutritional parameters, and also disease activity, length of TPN and hospital stay, were independent of glutamine substitution. Five (41%) patients in the gln þ group and three (25%) patients in the glnÀ group needed surgical intervention. Conclusion: Although limited by the sample size, these results do not support the hypothesis that glutamine substitution has an obvious biochemical or clinical benefit in patients with active IBD scheduled for total parenteral nutrition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Tak więc ESPEN nie zaleca stosowania glutaminy u pacjentów z tymi chorobami [35,36]. Wyniki dwóch badań z randomizacją nie wykazały korzystnego wpływu dojelitowego żywienia z glutaminą w porównaniu z żywieniem standardowym lub placebo na aktywność choroby Leśniowskiego-Crohna oraz na parametry kliniczne i antropometryczne [37,38]. Akobeng i wsp.…”

Section: Nieswoiste Choroby Zapalne Jelitunclassified

“…Akobeng i wsp. [37] wykazali w grupie 18 pacjentów z chorobą Leśniowskiego-Crohna, że dieta polimeryczna z 42-procentową zawartością glutaminy w stosunku do 4-procentowej zawartości tego aminokwasu nie wpływała istotnie na poziom kwaśnej globuliny osocza, liczbę płytek krwi i masę ciała. Den Hond i wsp.…”

Section: Nieswoiste Choroby Zapalne Jelitunclassified

Nutritional support with glutamine according to recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN)

Kędziora¹,

Słotwiński²,

Dąbrowska³

2010

View full text Add to dashboard Cite

StreszczenieW stanach stresu metabolicznego (np. urazy, zapalenia, oparzenia, choroby nowotworowe, kacheksja) glutamina wykorzystywana jest jako źródło energii w większych ilościach niż w stanie fizjologicznym i staje się związkiem warunkowo niezbędnym. Dlatego też w takich sytuacjach zalecana jest jej suplementacja. Europejskie Towarzystwo Żywienia Klinicznego i Metabolizmu (ESPEN) od 2005 r. przedstawia zalecenia żywieniowe dotyczące pozajelitowego lub dojelitowego stosowania glutaminy w poszczególnych jednostkach chorobowych i konkretnych sytuacjach klinicznych. Niniejsza praca ma na celu zebranie i uporządkowanie aktualnych zaleceń ESPEN dotyczących suplementacji tego aminokwasu zarówno w żywieniu enteralnym, jak i parenteralnym. AbstractIn conditions of metabolic stress (trauma, burns, cancer, cachexia) glutamine as a source of energy is used more than in the physiological state and becomes a conditionally essential amino acid. Because of this, glutamine should be supplemented in these conditions. The European Society for Clinical Nutrition and Metabolism (ESPEN) since 2005 has presented recommendations of glutamine's use in different diseases and clinical states. This article presents current recommendations of glutamine supplementation in both enteral and parenteral nutrition.

show abstract

Enteral nutritional therapy for induction of remission in Crohn's disease

Zachos

Tondeur

Griffiths

2001

The Cochrane Database of Systematic Reviews

142

102

View full text Add to dashboard Cite

Double-Blind Randomized Controlled Trial of Glutamine-Enriched Polymeric Diet in the Treatment of Active Crohn's Disease

Cited by 157 publications

References 27 publications

Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease

Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease

Nutritional support with glutamine according to recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN)

Enteral nutritional therapy for induction of remission in Crohn's disease

Contact Info

Product

Resources

About